Cancer Treatment Monitoring with EFIRM
By EZLife Bio on July 3, 2021
MDPI cancers has recently published an exciting paper regarding liquid biopsy and its potential applications in therapeutic treatment monitoring. A cohort of 22 lung cancer subjects with samples taken periodically over a period of 61 to 272 days was evaluated with EFIRM, NGS, and ddPCR.
This publication was a project including authors from EZLife Bio, the National Cancer Institute, and UCLA. Read more about it below!